Nedaa Skeik1, Brandon R Porten2, Erin Isaacson2, Jenny Seong2, Deana L Klosterman3, Ross F Garberich2, Jason Q Alexander4, Adnan Rizvi5, Jesse M Manunga5, Andrew Cragg6, John Graber7, Peter Alden8, Timothy Sullivan9. 1. Vascular Medicine, Minneapolis Heart Institute Vascular Medicine, Minneapolis, MN; Hyperbaric and Oxygen Center, Minneapolis Heart Institute Vascular Medicine, Minneapolis, MN; Thrombophilia and Anticoagulation Clinic, Minneapolis Heart Institute Vascular Medicine, Minneapolis, MN. Electronic address: Nedaa.Skeik@allina.com. 2. Minneapolis Heart Institute Foundation, Minneapolis, MN. 3. Hyperbaric Oxygen Clinic, Abbott Northwestern Hospital, Minneapolis, MN. 4. Minneapolis Heart Institute Foundation, Minneapolis, MN; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN. 5. Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN. 6. Minneapolis Heart Institute Foundation, Minneapolis, MN; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN; University of Minnesota, Minneapolis, MN. 7. Minneapolis Heart Institute Foundation, Minneapolis, MN; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN; Mission Surgery Program-Guatemala Surgery, Minneapolis, MN. 8. Minneapolis Heart Institute Foundation, Minneapolis, MN; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN; Wound Clinic at Abbott Northwestern Hospital, Minneapolis, MN. 9. Minneapolis Heart Institute Foundation, Minneapolis, MN; University of Minnesota, Minneapolis, MN; Vascular and Endovascular Surgery, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN; Abbott Northwestern Hospital Vascular Center, Minneapolis, MN.
Abstract
BACKGROUND: Hyperbaric oxygen (HBO) is used as an adjunctive therapy for a variety of indications. However, there is a lack of high-quality research evaluating HBO treatment outcomes for different indications available in the current literature. METHODS: We retrospectively reviewed all patients who underwent HBO therapy at a single hyperbaric center from January 2010 to December 2013 using predetermined criteria to analyze successful, improved, or failed treatment outcomes for the following indications: chronic refractory osteomyelitis, diabetic foot ulcer, failed flap or skin graft, osteoradionecrosis, soft tissue radiation necrosis, and multiple coexisting indications. RESULTS: Among the included 181 patients treated with adjunctive HBO at our center, 81.8% had either successful or improved treatment outcomes. A successful or improved outcome was observed in 82.6% of patients treated for chronic refractory osteomyelitis (n = 23), 74.1% for diabetic foot ulcer (n = 27), 75.7% for failed flap or skin graft (n = 33), 95.7% for osteoradionecrosis (n = 23), 88.1% for soft tissue radiation necrosis (n = 42), and 72.4% for multiple coexisting indications (n = 29). Among 4 patients treated for other indications, 100% of the cases were either successful or improved. CONCLUSIONS: This study has provided a comprehensive outcome survey of using HBO for the previously mentioned indications at our center. It supplements the literature with more evidence to support the consideration of HBO in different indications.
BACKGROUND: Hyperbaric oxygen (HBO) is used as an adjunctive therapy for a variety of indications. However, there is a lack of high-quality research evaluating HBO treatment outcomes for different indications available in the current literature. METHODS: We retrospectively reviewed all patients who underwent HBO therapy at a single hyperbaric center from January 2010 to December 2013 using predetermined criteria to analyze successful, improved, or failed treatment outcomes for the following indications: chronic refractory osteomyelitis, diabetic foot ulcer, failed flap or skin graft, osteoradionecrosis, soft tissue radiation necrosis, and multiple coexisting indications. RESULTS: Among the included 181 patients treated with adjunctive HBO at our center, 81.8% had either successful or improved treatment outcomes. A successful or improved outcome was observed in 82.6% of patients treated for chronic refractory osteomyelitis (n = 23), 74.1% for diabetic foot ulcer (n = 27), 75.7% for failed flap or skin graft (n = 33), 95.7% for osteoradionecrosis (n = 23), 88.1% for soft tissue radiation necrosis (n = 42), and 72.4% for multiple coexisting indications (n = 29). Among 4 patients treated for other indications, 100% of the cases were either successful or improved. CONCLUSIONS: This study has provided a comprehensive outcome survey of using HBO for the previously mentioned indications at our center. It supplements the literature with more evidence to support the consideration of HBO in different indications.
Authors: Ahmed Sultan; Glenn J Hanna; Danielle N Margalit; Nicole Chau; Laura A Goguen; Francisco M Marty; Guilherme Rabinowits; Jonathan D Schoenfeld; Stephen T Sonis; Tom Thomas; Roy B Tishler; Nathaniel S Treister; Alessandro Villa; Sook-Bin Woo; Robert Haddad; Hani Mawardi Journal: Oncologist Date: 2017-02-16
Authors: Christian Johann Lerche; Franziska Schwartz; Marie Theut; Emil Loldrup Fosbøl; Kasper Iversen; Henning Bundgaard; Niels Høiby; Claus Moser Journal: Front Cell Dev Biol Date: 2021-06-18